Healthcare & Life Sciences

Olympus Endoscope Suction Channel Design Patent Granted

The USPTO granted Olympus Corporation Patent US12605054B2 for an endoscope with a suction channel featuring a variable-diameter design. The suction channel includes a main body and a small-diameter distal portion satisfying the relational expression R1/R2>1.27, where R1 is the inner diameter of the channel main body and R2 is the inner diameter of the small-diameter channel portion. The patent contains 10 claims and covers technology for suctioning liquid along with crushed calculi during endoscopic procedures.

Edwards Lifesciences Heart Valve Repair Patent Granted

USPTO granted patent US12605248B2 to Edwards Lifesciences Corporation on April 21, 2026. The patent covers valve repair systems and leaflet clip devices for reducing regurgitation through native heart valves, including a delivery apparatus and clipping member that transforms from a delivery configuration to an implantation configuration via tensioning members. The patent names Lauren R. Freschauf and Ralph Schneider as inventors.

Avatar Medical Autostereoscopic Display Patent Granted

The USPTO granted patent US12605062B1 to Avatar Medical on April 21, 2026, covering a switchable autostereoscopic display system capable of rendering both stereoscopic 3D images and flat 2D images on a single display. The patent contains 15 claims and is classified under medical imaging CPC codes.

Balloon Device for Rigid Bronchoscope US12605060B1

The USPTO granted Patent US12605060B1 to inventors An Ho and David Stein for a balloon device configured for use with rigid bronchoscopes. The invention includes a balloon shaft member, a balloon member, and an inflation device, designed to fit snugly on the outside of a rigid bronchoscope to improve patient ventilation and prevent back bleeding during rigid bronchoscopy procedures.

Verathon US12605059B2 Dynamically Retractable Camera Laryngoscope

The USPTO granted patent US12605059B2 to Verathon Inc. for a dynamically retractable camera apparatus designed for video laryngoscopes. The invention comprises a video baton with a handle portion, a shuttle assembly that slides between extended and retracted positions, and a flexible coupling element connecting to an image capturing and lighting assembly. The patent application was filed on November 17, 2022, under application number 18056514, and contains 19 claims.

Medical Apparatus and Method for Operating Medical Apparatus

USPTO granted Patent US12605055B2 to FUJIFILM Corporation on April 21, 2026. The patent covers a medical apparatus that illuminates a subject and captures images of reflected light for examination purposes, including a light source, light receiving section, and image control processor.

Analyte Sensor Inserter Design Patent Granted April 21, 2026

The USPTO granted Design Patent USD1123164S1 for an analyte sensor inserter to inventors Shun Hui, Zhongyi Ding, and Guochang Li. The patent application (No. 35522868) was filed on October 18, 2024, and the design is classified under A61B 17/205, A61B 2017/925, and A61M 37/0015. One claim was allowed.

Wahoo Fitness Heart Rate Monitor Design Patent USD1123163S1

USPTO issued Design Patent USD1123163S1 to Wahoo Fitness L.L.C. for a heart rate monitor design. The patent contains one design claim and was filed on December 31, 2024. This grant provides Wahoo Fitness with exclusive design rights for the ornamental appearance of the heart rate monitor device in the United States.

Glimpse Diagnostics US12605057B2 Otoscope Patent Granted

USPTO granted patent US12605057B2 to Glimpse Diagnostics, Inc. on April 21, 2026 for a lighted otoscope speculum. The invention includes a body with neck and stopper, a cap with flange overhang, a channel with proximal and distal openings, and at least one light embedded within the neck near the distal tip. The patent contains 21 claims.

SCHUTHINK LLC Topographical Dental Abutment Design Patent USD1123160S1

USPTO granted Design Patent USD1123160S1 to SCHUTHINK LLC for a topographical dental abutment. The patent protects the ornamental design of the dental abutment component used in dental implant procedures. Inventor Stephen J. Chu filed the application on September 5, 2025 under Application No. 30021675.

Design Patent USD1123156S1 for Tongue Scraper Issued to LEZU VENTURES LLC

USPTO granted Design Patent USD1123156S1 for a tongue scraper to LEZU VENTURES LLC. The patent covers the ornamental design of the tongue scraper and lists Mike Sertyan as inventor. The application was filed on September 28, 2023.

Agnya Perceptive Eye Imaging Patent Granted Apr 21

USPTO granted Patent US12605061B2 to Agnya Perceptive Solutions, L.L.C. for an eye imaging system with a head-wearable positioning helmet, conformable liner with head location fiducials, and an articulating eye imager fixture with positioning indication system. The system enables automated fundus camera positioning for accurate image capture and analysis using machine learning models for patient evaluation, monitoring, or diagnosis.

Nanochon Chondrograft First in Human Early Feasibility Study - Panama

NIH has registered a First in Human early feasibility study for the Nanochon Chondrograft Implant, a device intended as a primary surgical treatment for adult patients with knee cartilage lesions. The single-arm study will enroll males and females aged 22 to 60 and is registered under NCT07542184.

Bedside Lung Ultrasound to Monitor Lung Recruitment in Obese Patients (NCT07542093)

The NIH ClinicalTrials.gov registry has posted a new prospective observational study (NCT07542093) evaluating Bedside Lung Ultrasound (LUS) as a monitoring tool for lung recruitment maneuvers in mechanically ventilated adult patients with morbid obesity (BMI ≥ 33 kg/m²) in the ICU. The study will use a standardized 12-zone ultrasound scan to calculate a Total Lung Ultrasound Score and identify optimal PEEP settings. Conditions studied include morbid obesity, respiratory failure, atelectasis, and ventilator-induced lung injury.

Pharmacogenetics and Model-Informed Optimisation of Hydroxyurea Study

The NIH registered NCT07543289, an observational prospective cohort pharmacokinetic study evaluating pharmacogenetics, pharmacodynamics, and pharmacokinetics of hydroxyurea therapy in 100 Nigerian patients with sickle cell disease. The study will develop PopPK and PK-PD models using Monolix and exposure-response analyses in R to support a precision medicine dosing algorithm for hydroxyurea in this population.

Sex Hormones and Kidney Function in Gender-Affirming Hormone Therapy, 60 Participants

The National Institutes of Health registered observational study NCT07542964 on April 21, 2026, investigating how sex hormones affect kidney function in individuals undergoing gender-affirming hormone therapy. The study will enroll 60 participants (30 men and 30 women, aged 18-40) who will undergo three study visits over one year, including kidney function measurements, kidney MRI, urine collection, and fat tissue sampling. Participants will not experience delays in starting gender-affirming hormone therapy.

iEUS-PCL AI System for Multimodal Diagnosis of Pancreatic Cystic Lesions

NIH ClinicalTrials.gov registered observational study NCT07543263 for an artificial intelligence system named iEUS-PCL designed to detect and diagnose pancreatic cystic lesions during endoscopic ultrasound examinations. The study will develop and validate the multimodal, multi-class diagnostic tool for clinical use.

Photobiomodulation Autism Trial for Children, NCT07542899

NIH has registered a new clinical trial (NCT07542899) evaluating photobiomodulation therapy on core symptoms of autism spectrum disorder in children. The study will combine photobiomodulation with physical therapy, occupational therapy, and speech therapy over a defined treatment period. Outcomes will be measured using standardized clinical scales assessing social interactions, communication, and behavior improvements.

RATS Sleeve Lobectomy After Neo-Chemo-IO for Non-Small Cell Lung Cancer

NIH's ClinicalTrials.gov has registered NCT07541521, a multicenter prospective observational study evaluating surgical difficulty and outcomes of robotic-assisted thoracoscopic surgery (RATS) sleeve lobectomy in patients with Stage IIB-III non-small cell lung cancer (NSCLC) following neoadjuvant chemoimmunotherapy. The study will track rates of unsuccessful surgery, associated factors, and surgeon-assessed intraoperative difficulty across multiple dimensions.

COPD Trial Compares Anoro, Ultibro, Spiolto to Tiotropium

ClinicalTrials.gov registered a Phase 4 crossover trial (NCT07541378) at Medical University of Białystok and University Hospital Pulmonology Outpatient Clinic in Poland. The study will directly compare three LABA/LAMA fixed-dose combinations (umeclidinium/vilanterol, indacaterol/glycopyrronium, tiotropium/olodaterol) against tiotropium monotherapy in approximately 100 stable COPD patients over four 28-day treatment periods with 7-day washouts.

CAM Study for Hematologic Malignancies, France, NCT07541326

NIH's ClinicalTrials.gov has registered study NCT07541326, an observational study examining the use of complementary and alternative medicine (CAM) among patients with hematologic malignancies in France. The study uses a questionnaire-based approach to collect data on CAM prevalence, types, and purposes among this patient population. Hematologic malignancies are underrepresented in existing CAM research, with a 2015 French study showing only 2% hematologic cases among all cancer types surveyed.

NIH Registers Aspirin 50mg vs 100mg CVD Study NCT07542860

NIH's ClinicalTrials.gov has registered a new prospective cohort study (NCT07542860) evaluating 50mg versus 100mg daily aspirin for secondary prevention of atherosclerotic cardiovascular disease in approximately 5,448 Chinese patients aged 60 years and older, with follow-up extending to approximately 6 years through the LAPIS cohort extension.

US12605412B2 - Microbial Compositions for Improving Anticancer Treatment Efficacy

USPTO granted Patent US12605412B2 to Institut Gustave Roussy, covering microbial compositions for enhancing the efficacy of anticancer treatments. The patent claims compositions combining specific bacterial species (Alistipes senegalensis, Dorea longicatena, Eubacterium siraeum) with immune checkpoint inhibitors and/or tyrosine kinase inhibitors, along with diagnostic methods for assessing patient responsiveness to such treatments.

Akkermansia muciniphila AK32 Strain for Improving Intestinal Function

The USPTO granted patent US12605414B2 to The Asan Foundation for an Akkermansia muciniphila AK32 strain (Accession No. KCTC 14172BP) and its use for preventing or improving intestinal damage. The patent covers the bacterial strain itself as well as a method for administering an effective amount of the strain or its culture as an active ingredient to treat intestinal damage. Three claims are included in the granted patent.

NB Science M3 Mutant Peptide Patent for Myopathy, Obesity, Diabetes

USPTO granted patent US12605431B2 to NB SCIENCE CO., LTD. on April 21, 2026. The patent covers an M3 mutant peptide composition for treating or preventing myopathy, obesity, or diabetes, listing five claims under CPC classifications including A61K 38/4886 and A61P 3/04. The application (18267252) was filed on December 14, 2021.

hUCB Plasma Therapeutic for Neurodegenerative Diseases

The USPTO granted patent US12605409B1 to the University of South Florida covering a method of treating neurodegenerative diseases using plasma derived from human umbilical cord blood (hUCB plasma). The patent discloses that hUCB plasma attenuated hyperactive mitogen responses and reduced caspase 3/7 activity in ALS patient cells, supporting therapeutic efficacy. Assignee: University of South Florida; inventors: Svitlana Garbuzova-Davis, Jared Carl Ehrhart, and Paul R. Sanberg.

Technion Patents Heparanase-Neutralizing A54 mAb

The USPTO granted patent US12606637B2 to Technion Research & Development Foundation Limited on April 21, 2026. The patent covers heparanase-neutralizing monoclonal antibody A54 (IgG-1 mAb), its epitope HBD-II, pharmaceutical compositions, and uses for treating cancer, inflammation, viral infections, diabetes, and related complications. The patent also discloses combinatorial cancer therapies combining the A54 mAb with chemotherapy or radiation.

Nanjing Legend Biotech CAR-T Patent, GPC2 Cancer Immunotherapy

The USPTO granted Patent US12606635B2 to Nanjing Legend Biotech Co., Ltd. covering GPC2-specific antibodies, antigen binding fragments, and chimeric antigen receptor (CAR) constructs for cancer immunotherapy. The patent encompasses T cells engineered with the disclosed CAR constructs. The application (No. 17910608) was filed March 12, 2021, and contains 19 claims.

Shanghai Henlius Biotech Anti-CD73 Antibody Patent US12606633B2

The USPTO granted Patent US12606633B2 to Shanghai Henlius Biotech, Inc. on April 21, 2026, covering anti-CD73 antibodies, variants, and antigen binding fragments that bind human CD73 with high affinity and suppress enzymatic activity. The patent includes 17 claims and covers isolated nucleic acid molecules, expression vectors, host cells, and related pharmaceutical compositions for treating subjects.

CD25 Chimeric Antigen Receptor Patent Granted to Montefiore Medical Center

USPTO granted US Patent US12606630B2 to Montefiore Medical Center covering CD25 chimeric antigen receptors and their therapeutic uses. The patent, applied for in August 2020, contains 19 claims covering compositions and methods for immune enhancement and cancer treatment. This grant confers exclusive intellectual property rights to the assignee for the claimed biological compositions and treatment methods.

DLL3 Targeting CAR-T Cell Therapy Patent Granted to Allogene Therapeutics

The USPTO granted Patent US12606623B2 to Allogene Therapeutics, Inc. covering DLL3 binding agents and chimeric antigen receptors (CARs) for use in immune cell therapies, specifically CAR-T cells. The patent includes 26 claims and covers methods of making and using DLL3-specific CARs. This grant establishes exclusive IP rights for the assignee in the specified therapeutic domain.

NovoMab BioPharmaceuticals Inc CTLA-4 Antibody Patent US12606624B2

The USPTO granted Patent US12606624B2 to NovoMab BioPharmaceuticals Inc covering an antibody that specifically binds to human CTLA-4. The patent discloses three complementarity-determining regions (CDR1-3) and applications in medicaments and kits for potential tumor growth inhibition. The patent application (18456503) was filed on August 27, 2023.

Anti-CD40 Antibodies and Methods of Use (Apexigen Patent Grant)

USPTO granted US Patent 12,606,632 B2 to Apexigen, Inc. on April 21, 2026. The patent covers high affinity anti-CD40 monoclonal antibodies and related compositions for therapeutic use in cancer and other diseases. Named inventors are Yongke Zhang, Guo-Liang Yu, and Weimin Zhu.

Surrozen Operating Inc. Secures Anti-Frizzled Antibody Patent

The USPTO granted Patent US12606629B2 to Surrozen Operating, Inc. on April 21, 2026. The patent covers monospecific anti-Frizzled monoclonal antibodies and related compositions for therapeutic applications. The application, filed July 2, 2020, received 10 claims under CPC classifications including C07K 16/2863.

US12606631B2 - ETAR Antibodies, Patent Grant

USPTO granted Patent US12606631B2 to REMD Biotherapeutics Inc for isolated antibodies that specifically bind endothelin A receptor (ETAR). The antibodies have high affinity for ETAR, block ET-1 binding to ETAR, exhibit reduced immunogenicity, and have longer serum half-life compared to small molecule ETAR antagonists. Seven claims were allowed.

Modular System for Cold Water Exposure Therapy Using Directed Ice Impingement

The USPTO granted patent US12605274B1 to Brrr Tech, LLC on April 21, 2026, covering a modular cold water exposure therapy system using directed ice impingement. The system includes an ice container configured to form and hold treatment ice, an agitator module with pump and impingement ports for circulating chilled water, and mobile app connectivity for session tracking. The patent protects methods for forming treatment ice, circulating treatment water, and conducting controlled cold exposure sessions in clinical and at-home settings.

Liquid and Waste Collection System US12605270B2

USPTO granted Patent US12605270B2 to Babyation Inc. for a liquid and waste collection system using pressure and liquid tubing connected to a pressure source and liquid collector. The system collects liquid without passing it through the pump. The patent, filed February 18, 2022 under Application No. 17676028, contains 10 claims and covers CPC classifications A61F 5/455, A61F 5/453, A61F 5/4408, and A61F 13/15.

US12605271B2 External Female Catheter

The USPTO granted Patent US12605271B2 to inventor Roxanna Stead for an external urinary catheterization device designed for females. The device comprises a shell with a cutout positioned over the vulva, a fill material that wicks urine into an interior space, and a tube connected to a vacuum assembly for urine removal. The patent contains 11 claims and was filed on December 22, 2022.

Prolapse Corrective Device, US Patent 12605273B2

The USPTO granted Patent 12605273B2 to inventor Juan Llopis Manzanera on April 21, 2026, for a prolapse corrective device. The device comprises a single-piece structure with a dome-shaped head, two opposing diverging arms, and a connecting strap, adopting a dished isosceles triangle shape by default that is elastically deformable for insertion and extraction.

USPTO Grants Medical Device Patent US12605268B2 to Horizon IP Tech

USPTO granted Patent US12605268B2 to HORIZON IP TECH, LLC on April 21, 2026. The patent covers a medical device comprising a plastic film with insufficient intrinsic stability to retain a planar shape against gravity, supported by a structure that inhibits at least 80% of the film from deforming regardless of orientation. The application (17736284) was filed May 4, 2022, and the patent contains 8 claims.

Finger Pain Relief Device Patent US12605267B2

The USPTO granted patent US12605267B2 to inventor Jafar Vossoughi on April 21, 2026, covering a device and method to maintain distance between bones of a finger for pain relief. The patent describes an apparatus with engaging members and adjustable rod assemblies that control the gap between finger bones across a joint. The application was filed September 29, 2023, under application number 18478190, with 14 claims allowed.

Urinary Catheter Collection Bag with Replaceable Filter, US12605269B1

The USPTO granted patent US12605269B1 to six inventors for a urinary catheter urine collection system featuring a removable blockage filter positioned between the collection bag and drainage tube. The system includes a flow valve with open and closed configurations that selectively directs urine through the filter to trap blockage material. The patent, granted April 21, 2026, claims 20 patent claims covering the replaceable filter cup design with wall slits.

Thumb Brace Patent US12605266B1 - Bullseye Brace

The USPTO granted patent US12605266B1 to Bullseye Brace, Inc. (inventor Jeffrey B Stearns) on April 21, 2026 for a sheath lacing arrangement and associated carpometacarpal (CMC) thumb brace. The patent includes 14 claims covering the brace's design and functionality for limiting thumb and CMC joint range of motion. The filing date was October 13, 2023, under application number 18486640.

Orthopedic Corset Patent US12605265B2, 21st Apr

The USPTO granted Patent US12605265B2 on April 21, 2026, to inventor Kathrine A. Johns for an orthopedic back support corset design. The invention features a back-support panel with bonings, a lacing system for tightness adjustment, and a multi-panel construction with front-side fastener. The patent contains 20 claims under CPC classifications A61F 5/028, A61F 5/01, and related subclasses.

Soochow University Patent: Aniline Acid Anhydride Preparation Method

The USPTO granted Patent US12606530B2 to Soochow University on April 21, 2026, covering an aniline acid anhydride, its preparation method, and a polyaminoacid graft chain. The preparation involves an addition-elimination reaction between N-phenyl amino acid and Boc anhydride under acidic conditions, followed by cyclization under nitrogen to obtain the aniline anhydride. The polyaminoacid graft chain is intended for covalent bonding with fiber materials to improve water-repellent fabric fastness while maintaining wearability.

BASF SE Patent, Oxadiazole Preparation, 19 Claims

The USPTO granted Patent US12606532B2 to BASF SE for a process to prepare substituted 3-aryl-5-trifluoromethyl-1,2,4-oxadiazoles. The process involves reacting amidoxime compounds with a haloacetic ester in the presence of a solvent and base. The patent contains 19 claims with inventors Florian Vogt, Kailaskumar Borate, Bernd Wolf, Christopher Koradin, Joachim Gebhardt, Roland Goetz, and Harish Shinde. The application was filed February 1, 2021.

INFEX Therapeutics Pyrrole Acid Synthesis Patent Grant

The USPTO granted patent US12606524B2 to INFEX Therapeutics Limited for a novel method of synthesizing pyrrole acid derivatives that function as metallo-β-lactamase inhibitors. These compounds are designed for use in combination with carbapenem antibacterial agents to treat bacterial infections. The patent claims priority to application 18246777, filed October 6, 2021, and contains 3 claims under CPC classification C07D 207/48.

Daiichi Sankyo SF-1 Antagonist 3-Phenylpropylamine Derivative Patent

The USPTO granted patent US12606533B2 to Daiichi Sankyo Company, Limited for a 3-phenylpropylamine derivative compound exhibiting SF-1 antagonist activity. The patent contains 29 claims and relates to the compound as well as polyfunctional molecules containing the compound moiety, including SF-1 degraders.

Kumquat Biosciences Heterocycle Patent Granted Apr 21

The USPTO granted patent US12606572B2 to Kumquat Biosciences Inc. on April 21, 2026. The patent covers substituted heterocycle compounds and methods for reducing signaling output of oncogenic proteins. The patent application (19352234) was filed October 7, 2025, and the granted patent contains 20 claims classified under C07D 519/00, A61P 35/00, and A61K 31/553.

Helsinn Healthcare SA NK-1 Antagonist Patent Granted Apr 21

USPTO granted Patent US12606527B2 to Helsinn Healthcare SA on April 21, 2026, for crystalline forms of an NK-1 antagonist useful in treating induced vomiting and other disorders. The patent application (18772244) was filed July 14, 2024, and contains 18 claims classified under CPC C07D 213/75 and related pharmaceutical categories.